视频直播
Direct Genotyping from Blood & FFPE Biopsies: Novel Inhibitor-Tolerant Master Mixes & Their Applications in Molecular Diagnosis
DNA genotyping is a powerful technology that allows the identification of genetic variations that can lead to an increased risk of developing certain diseases. Additionally, genotyping has a fundamental role in companion diagnostics, as it enables the characterization of patients’ genetic profiles that can be used to guide treatment decisions.
Here, we will introduce two novel master mixes developed to provide PCR-based identification of mutations directly from the clinical samples, such as blood, plasma or FFPE tissue, bypassing DNA extraction and streamlining the analysis of both liquid and tissue biopsies.
主讲嘉宾：
Mihai-Nicolae Podaru, PhD (R&D Senior Scientist, Meridian Bioscience)
Moderator:
Steve Hawkins, PhD (Product Marketing Manager, Meridian Bioscience)
Transforming Cancer Detection with Liquid Biopsy
Liquid biopsy is fast becoming the method of choice for cancer diagnosis in the field of precision medicine, allowing oncologists to choose a targeted therapy, monitor treatment resistance and detect minimal residual disease, without patients undergoing an invasive procedure. Liquid biopsy utilizes bodily fluids such as blood, stool, urine and saliva to detect cancer biomarkers earlier than conventional methods such as tissue biopsy. It is also useful to screen for drug-resistant subpopulations, micro-metastases, minimum residual disease and disease relapse. The non-invasive approach of liquid biopsies enables samples to be taken easily and repeatedly over the course of a patient’s treatment, overcoming the inherent shortcomings and risks of surgical tissue biopsies. This panel discussion will review how liquid biopsy is opening up new avenues in cancer detection and continuous monitoring for personalized cancer treatment, as well as the screening of cancer markers for therapeutic resistance. Four industrial leaders in the field of molecular diagnostics will come together to discuss the current status of liquid biopsy for cancer screening, as well as how modern technologies are changing the landscape of cancer detection and CDx.
Panelists:
Chris Sale (CEO, Nonacus, UK)
Shidong Jia, PhD (CEO, Predicine, USA)
Hongjun (Harry) Yang, PhD (Senior VP of CDx, DiaCarta, USA)
Florent Chang-Pi-Hin PhD (VP of R&D, Meridian Bioscience, USA)
Moderator:
Steve Hawkins, PhD (Product Marketing Manager, Meridian Bioscience)
Top Reasons for Using Animal-Free HAMA/RF Immunoassay Interference Blockers
Immunoassay interference can cause false-positive and false-negative test results, leading to misinterpretation and improper patient diagnosis. The most common causes of interference are due to Human Anti-Mouse Antibodies (HAMA), Rheumatoid Factor (RF), and Heterophilic Antibodies (HA). HAMA are the most prevalent and are identified in up to 25% of the patient population. Combined with HA, they represent the most significant factors leading to false positive immunoassay results.
Avoiding immunoassay interference requires blockers to be included in every immunoassay. Historically, animal-based interference blockers have been used to improve assay accuracy; however, they are susceptible to cross-reactivity with assay reagents, lot-to-lot variability, and supply shortages – as seen during the COVID-19 pandemic. Meridian’s new animal-free commercial blockers, K-BlockTM and Mouse-FREE IgG, are the next-generation solution for blocking HAMA/RF/HA that overcomes the ethical concerns and supply problems in using animal-derived blockers.
In this webinar you will learn the advantages of using animal-free immunoassay blockers and their performance.
主讲嘉宾：
Ryan Hughes Ph.D., (Life Science Immunology Product Manager, Meridian Bioscience)
Andy Gaspar Ph.D., (Life Science Technical Operations and Development Manager, Meridian Bioscience)
Moderator:
Steve Hawkins, PhD (Product Marketing Manager, Meridian Bioscience)
The Future of Molecular Reagent Technologies: Transforming Infectious Disease Testing
The molecular diagnostic approach for infectious disease such as STDs, tropical, and respiratory disease has seen significant development in the past twelve months, driven by a demand for better, faster, higher sensitivity assays, that can detect asymptomatic carriers. Traditionally, lab-based tests using blood samples have been the mainstay for molecular testing, however home-based, extraction-free tests, using alternative sample types (saliva, urine, stool) are now highly sought after, but pose significant challenges in assay development for both lab-based and point of care (POC) applications.
迈迪安作为全球领先的分子诊断试剂生产商，提供一系列直扩型分子试剂，包括抗抑性qPCR/RT-qPCR试剂，适用于LAMP检测的Bst酶和反应液，以及针对不同样本类型的可干燥抗抑性试剂。本次直播中，将重点介绍迈迪安为免核酸提取分子检测的解决方案。
- New nucleic acid amplification chemistries that simplify direct detection
- Optimizing assay performance per sample types (e.g. blood, saliva, urine, stool)
- The latest technologies that can reduce your cold-chain management
Presenters
Michele Amasio, Ph.D.
Research and Development Senior Manager
Steve Hawkins
Ph.D. – Product Marketing Manager
Ultra-fast Point-of-Care MDx development with new, sensitive LAMP master mixes
The COVID-19 pandemic accelerated the adoption of point-of-care molecular technologies that offer quick sample to results, high sensitivity, lower cost and widespread accessibility.
This webinar will cover new market-leading reagent solutions for loop-mediated isothermal amplification (LAMP) assays, which simplify assay development, speed up assay turnaround time, and deliver highly sensitive and specific amplification without DNA or RNA extraction.
Presenters
Elda Iljazi Ph.D.
Senior Scientist Meridian Bioscience
Highly sensitive qPCR detection of biomarkers from liquid biopsies
Liquid biopsy is a non-invasive alternative to tissue biopsy based on ultra-sensitive detection of tumor-derived material such as ctRNA and ctDNA from biofluids, including blood, urine, stool, saliva, and sputum. qPCR based liquid biopsy possesses several advantages in cost and throughput, when compared to other technologies like NGS and ddPCR. In this talk, we will discuss Meridian’s new advances in inhibitor tolerant qPCR based liquid biopsy, that reduces the cost and complexity of these assays, while enabling ultra-sensitive detection from very low concentration cancer markers.
Presenters
Steve Hawkins
Ph.D. – Product Marketing Manager
Michele Amasio, Ph.D.
Research and Development Senior Manager
Meridian’s solution to detecting DNA or RNA directly from whole blood
Direct qPCR has many advantages over traditional qPCR workflows that involve DNA/RNA extraction. However, achieving high sensitivity with direct qPCR using whole blood samples has been challenging due to the presence of qPCR inhibitors within the sample (such as heme, salts, and proteins), and preservatives or anti-coagulants that are added during the sample collection process. The inhibitors can negatively impact the performance of the enzymes used in qPCR and RT-qPCR and they limit the amount of sample that can be added to the reaction, overall reducing the assay sensitivity and accuracy. In this talk, we will be discussing Meridian’s novel solution to overcome PCR inhibitors in direct qPCR and RT-qPCR, enabling greater sensitivity for direct detection from whole blood, improving assay reproducibility, and reducing assay development time.
Presenters
Thomas Fouqueau, PhD
Acting Team Leader, R&D, Meridian Life Science
Rachel Currier, PhD
Acting Team Leader, R&D, Meridian Life Science
主题： LAMP试剂开发技巧及关键原料选择 直播内容简介
等温聚合酶链反应，如环介导等温扩增 (LAMP)已经成为一种适用于POCT平台的理想方法。LAMP是在2000年由日本荣研化学株式会社纳富继宣博士发明的新型扩增技术。它与传统的qPCR都具有快速、高灵敏度和特异性等共同优势，同时还能满足基本在任何场所（从机场、学校到偏远的诊所）可完成检测的需求，从而极大地推进了POCT市场。 越来越多的IVD厂家开始介入LAMP领域的开发。
.
迈迪安作为全球诊断厂商首选的上游原料试剂生产商，提供一系列开发LAMP检测的高性能Bst酶，免提取抗抑性LAMP反应液，可冻干LAMP试剂等，可为开发分子POCT诊断提供完整的解决方案。本次直播中，将重点分享LAMP技术及其开发和优化，以及迈迪安生物提供的解决方案。
主讲嘉宾：
米佳 北京蓝谱生物技术开发有限公司副总经理 李伟 迈迪安生物科技高级商务经理 Alpha Chen 迈迪安生物科技市场&产品技术
主题： 免核酸提取直扩：让分子诊断更简单快速 直播内容简介
PCR技术因其高灵敏度和特异性已成为分子诊断市场的最大领域。临床和环境样本中含有不同的PCR抑制物会影响分子检测的准确度和灵敏度，因此通常来说，PCR检测需要先从样本中提取DNA/RNA。 核酸提取纯化的步骤多、时间长，核酸也有可能在提取过程中损失而降低检测的灵敏度。 免核酸提取的直接扩增则可以克服这一难题。该技术对扩增体系要求有极强的抗抑制物干扰能力和极高的特异扩增能力，从而可直接对样本进行高灵敏的扩增，简化操作步骤，避免处理样本时的交叉污染，减少检测试剂、仪器和时间成本，提高样本出结果的周转时间，是开发POCT平台的理想选择。
迈迪安作为全球领先的分子诊断试剂生产商，提供一系列直扩型分子试剂，包括抗抑性qPCR/RT-qPCR试剂，适用于LAMP检测的Bst酶和反应液，以及针对不同样本类型的可干燥抗抑性试剂。本次直播中，将重点介绍迈迪安为免核酸提取分子检测的解决方案。
- The new advances in the LAMP and qPCR assay development for POC
主讲嘉宾：
Alpha Chen 迈迪安产品技术和市场营销 Rachel Currier 迈迪安生物科技分子研发经理
主题： 分子POCT诊断试剂研发面临的挑战及解决方案:LAMP vs. qPCR 直播内容简介
POCT 即时检测 (Point-of-Care Testing) ，是在采样现场进行的、利用便携式分析仪器及配套试剂快速得到检测结果的一种检测方式。 近年来，POCT在诊断市场上迅速获得青睐，尤其是在传染性疾病诊断上。2020年初的新冠疫情，因其大规模基层检测需求，更是加速了传染类疾病POCT的快速发展，其中分子POCT崭露头角，迅速登上诊断舞台。qPCR目前是分子检测的黄金标准，但是它需要在实验室里使用专业的设备和研究员进行操作。等温聚合酶链反应，如环介导等温扩增 (LAMP)已经成为一种适用于POCT平台的理想方法。它与传统的qPCR都具有快速、高灵敏度和特异性等共同优势，同时还能满足基本在任何场所（从机场、学校到偏远的诊所）可完成检测的需求，从而极大地推进了POCT市场。
迈迪安生物科技公司（Meridian Life Science）早在 2010 年首次利用LAMP技术开发出了第一个用于诊断艰难梭菌的商业化诊断试剂及设备（Alethia®）。 从那时起，我们在Alethia®平台上开发并商业化了一系列用于传染病诊断的检测试剂，比如 A 组链球菌、B 组链球菌、一型和二型单纯疱疹病毒、百日咳，肺炎支原体，衣原体、淋病和疟疾等。迈迪安作为全球诊断厂商首选的上游原料试剂生产商，提供一系列常温稳定的干燥型分子试剂，包括可冻干LAMP/RT-LAMP试剂，可为开发分子POCT诊断提供完整的解决方案。我们的Alethia® 的系类产品全部采用冻干试剂。
-
迈迪安生物科技公司（Meridian Life Science）早在 2010 年首次利用LAMP技术开发出了第一个用于诊断艰难梭菌的商业化诊断试剂及设备（Alethia®）。 从那时起，我们在Alethia®平台上开发并商业化了一系列用于传染病诊断的检测试剂，比如 A 组链球菌、B 组链球菌、一型和二型单纯疱疹病毒、百日咳，肺炎支原体，衣原体、淋病和疟疾等。迈迪安作为全球诊断厂商首选的上游原料试剂生产商，提供一系列常温稳定的干燥型分子试剂，包括可冻干LAMP/RT-LAMP试剂，可为开发分子POCT诊断提供完整的解决方案。我们的Alethia® 的系类产品全部采用冻干试剂。
Presenters:
Dr Steve Hawkins – Product Marketing Manager
Dr Michele Amasio – Research and Development Manager
Introducing a new advancement in AgBio assay development for creating field-friendly, highly sensitive and cost-effective molecular plant assays.
- Create ambient temperature stable assays without the need for lyophilization
- Simplify workflow with direct qPCR for crude plant lysates
- Improve assay sensitivity for better LOD
- Quantify the presence of GMOs more accurately
- Speed up sample to results
Presenter:
Dr Steve Hawkins – Product Marketing Manager
迈迪安提供全面解决方案
Meridian offers diagnostic manufacturers the complete solution with over 3,000 antigens and antibodies covering more than 500 diseases and an extensive range of specialty qPCR/RT-qPCR master mixes and molecular enzymes all manufactured under ISO13485 regulations.
子午线搜索
与我们的专业团队联系
想了解更多迈迪安免疫和分子产品信息？欢迎与我们联系